A detailed history of Mitsubishi Ufj Kokusai Asset Management Co., Ltd. transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Mitsubishi Ufj Kokusai Asset Management Co., Ltd. holds 37,726 shares of IDYA stock, worth $1.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,726
Previous 5,171 629.57%
Holding current value
$1.01 Million
Previous $181,000 560.22%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$30.37 - $43.05 $988,695 - $1.4 Million
32,555 Added 629.57%
37,726 $1.2 Million
Q2 2024

Aug 12, 2024

SELL
$34.37 - $43.46 $12,854 - $16,254
-374 Reduced 6.74%
5,171 $181,000
Q1 2024

May 09, 2024

SELL
$34.2 - $47.13 $8,686 - $11,971
-254 Reduced 4.38%
5,545 $243,000
Q4 2023

Feb 08, 2024

SELL
$24.59 - $35.83 $96,786 - $141,026
-3,936 Reduced 40.43%
5,799 $206,000
Q3 2023

Nov 07, 2023

BUY
$21.07 - $29.77 $11,714 - $16,552
556 Added 6.06%
9,735 $262,000
Q2 2023

Aug 09, 2023

SELL
$13.33 - $25.53 $31,085 - $59,535
-2,332 Reduced 20.26%
9,179 $215,000
Q1 2023

May 08, 2023

BUY
$13.49 - $18.72 $14,609 - $20,273
1,083 Added 10.39%
11,511 $158,000
Q4 2022

Feb 07, 2023

SELL
$14.47 - $18.17 $99,003 - $124,319
-6,842 Reduced 39.62%
10,428 $189,000
Q2 2022

Aug 04, 2022

BUY
$8.28 - $13.88 $56,751 - $95,133
6,854 Added 65.8%
17,270 $238,000
Q1 2022

May 09, 2022

BUY
$11.18 - $24.02 $13,091 - $28,127
1,171 Added 12.67%
10,416 $117,000
Q4 2021

Feb 07, 2022

BUY
$20.95 - $26.88 $193,682 - $248,505
9,245 New
9,245 $222,000

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.29B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.